Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon May 01, 2015 4:18pm
199 Views
Post# 23686702

RE:RE:RE:Is it possible Don is setting up the lateral move to Zenith

RE:RE:RE:Is it possible Don is setting up the lateral move to Zenith JK, I'm sure she has an employment contract with Zenith which could have a myriad of provisions in it but it would certainly have an exit strategy built in which would cover various termination scenarios.  Perhaps we will get some clarification mid month, but it is a private company so maybe not regarding her departure.

GV, to your point about bringing H.S. in only to sell the company whole.  That could work very well for H.S. as a sale of RVX to a big pharma could still include the license agreement for H.S.  Pretty good deal if you could get a license deal and make an immediate profit on your capital investment.  That kind of deal is something one might expect from a company with close ties to Goldman-Sachs.  As you said though there could very well be another regional deal on the boil or for that matter could be just speculation floating around with no substance.  I guess we find out in due time.  Nice to dream though haha :)


Bullboard Posts